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Objective: To explore the potential for community 
pharmacist prescribing in terms of usefulness, 
pharmacists’ confidence, and appropriateness, in the 
context of asthma management.  
Methods: Twenty community pharmacists were recruited 
using convenience sampling from a group of trained 
practitioners who had already delivered asthma services. 
These pharmacists were asked to complete a scenario-
based questionnaire (9 scenarios) modelled on information 
from real patients. Pharmacist interventions were 
independently reviewed and rated on their 
appropriateness according to the Respiratory Therapeutic 
Guidelines (TG) by three expert researchers.  
Results: In seven of nine scenarios (78%), the most 
common prescribing intervention made by pharmacists 
agreed with TG recommendations. Although the 
prescribing intervention was appropriate in the majority of 
cases, the execution of such interventions was not in line 
with guidelines (i.e. dosage or frequency) in the majority of 
scenarios. Due to this, only 47% (76/162) of the 
interventions overall were considered appropriate. 
However, pharmacists were deemed to be often following 
common clinical practice for asthma prescribing. Therefore 
81% (132/162) of prescribing interventions were consistent 
with clinical practice, which is often not guideline driven, 
indicating a need for specific training in prescribing 
according to guidelines. Pharmacists reported that they 
were confident in making prescribing interventions and 
that this would be very useful in their management of the 
patients in the scenarios.  
Conclusion: Community pharmacists may be able to 
prescribe asthma medications appropriately to help 
achieve good outcomes for their patients. However, further 
training in the guidelines for prescribing are required if 
pharmacists are to support asthma management in this 
way. 
 
Keywords: Asthma; Drug Prescriptions; Community 
Pharmacy Services; Professional Practice; Professional 




Asthma rates in Australia are comparatively high 
internationally1, and asthma control amongst these 
patients is generally inadequate.2,3 In addition to 
                                            
*
Tamer HANNA. B.Pharm(Hons). The University of 
Sydney. Sydney, NSW (Australia). 
Beata BAJOREK. B.Pharm(Hons), Dip.Hosp.Pharm, 
GradCertEdStud (HigherEd), PhD. Associate Professor. 
University of Technology Sydney. Sydney, NSW 
(Australia). 
Kate LEMAY. B.Pharm, M.A. Project Manager. Woolcock 
Institute of Medical Research, The University of Sydney. 
Sydney, NSW (Australia). 
Carol L. ARMOUR. B.Pharm(Hons), PhD. Professor of 
Pharmacology, Director. Woolcock Institute of Medical 
Research, The University of Sydney. Sydney, NSW 
(Australia). carol.armour@sydney.edu.au 
clinical consequences, asthma poses a great 
economic load on the Australian health sector and 
individual patient.1,4 This prevalence and morbidity 
of asthma in Australia have led to a focus on its 
treatment, however the standard of current practice 
is less than ideal.5,6 Given the focus on a more 
multidisciplinary model of primary care, the 
utilisation of the pharmacist’s skills may help. 
Asthma management programs using specially 
trained pharmacists have been developed and 
proven to be successful in terms of clinical, 
economic and humanistic outcomes.7-9  
However, there is scope for pharmacists to do 
more. Pharmacists in other countries, such as the 
UK, USA and Canada, have adopted expanded 
prescribing roles into their practice.10-14 Broadly, 
these models of prescribing are either independent 
or dependent (i.e. collaborative with another 
prescriber) in nature.15 Supplementary prescribing, 
a form of dependent prescribing, is the most utilised 
and preferred approach, where a pharmacist can 
develop, in consultation with another prescriber, a 
patient-specific clinical management plan under 
which he/she can prescribe.10 In Australia, 
momentum for the structured and rational 
implementation of pharmacist prescribing has 
developed through initiatives such as the “Health 
Professionals Prescribing Project”16 and Prescribing 
Competencies Framework17 with input from the 
Pharmacist Prescribing Collaborative of Australia 
and New Zealand (PPCANZ). Australian 
pharmacists already ‘prescribe’ over-the-counter 
“Pharmacy/Pharmacist Only” medicines, and with a 
framework of prescribing already in place, 
pharmacist prescribing in Australia can very much 
complement the scope of practice.18 
Literature on pharmacist prescribing in Australia in 
primary health care is limited, but evolving. To date, 
much of the Australian research has focused on 
exploring the practice landscape to ascertain its 
readiness for pharmacist prescribing, including: 
exploring views of pharmacists19-22, general 
practitioners23, and clients15; identifying needs and 
preferences for training and skill development24; 
surveying pharmacists’ experiences of training 
opportunities25,26; and developing frameworks for 
the implementation of pharmacist prescribing.27 
Some pilot studies have explored the 
implementation of pharmacist prescribing in hospital 
practice, with a particular focus on anticoagulation 
or specific settings (e.g. preadmission clinics).28,29 A 
more recent study conducted in the preadmission 
clinic of a tertiary hospital has shown that 
pharmacist-prescribed inpatient medication charts 
can improve medication safety (i.e. fewer significant 
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omissions of medicines, less prescribing errors) and 
maintain optimal prophylactic therapy (i.e. 
prevention of venous thromboembolism).30 Whilst 
the hospital setting provides encouraging findings, 
particularly in providing data that may translate into 
improved outcomes and supporting the role of the 
pharmacist in this setting, additional research is 
needed to determine the potential for pharmacist 
prescribing in Australian community pharmacies, 
with a particular focus on high priority disease 
states such as asthma. Asthma also falls within a 
limited range of indications that pharmacists have 
identified as being suitable for independent 
prescribing, despite the general preference of 
pharmacists for supplementary prescribing31, 
highlighting their level of confidence in this area. 
Targeting chronic diseases, such as asthma, is 
underpinned by the Health Reform agenda, where 
the National Primary Health Strategy31 emphasises 
‘Better management of chronic conditions’ as one of 
its priority directions for change, and includes a 
‘skilled workforce’ as one of the five key building 
blocks. In acknowledging the need for patient-
centred care in contemporary practice, studies have 
shown that patients themselves are ‘overwhelmingly 
positive’ in their attitude toward pharmacist 
prescribing in the primary care setting.32 
This study aimed to explore the potential for 
prescribing by pharmacists in the management of 
patients with asthma in primary care using a 
scenario based approach, focusing on usefulness, 
pharmacists’ confidence, and appropriateness.  
 
METHODS  
A scenario-based questionnaire was designed and 
administered in August-September 2010, and 
approved by the institutional Human Research 
Ethics Committee. This was based on a previous 
Australian study of pharmacist prescribing33 and 
comprised nine scenarios describing patients with 
asthma (Table 1). Each scenario depicted clinical 
features of asthma control and basic demographics, 
and was modelled on de-identified information from 
real-life patients.9 It was stated that each patient 
had no other disease, no issues with inhaler 
technique or adherence, and took no other 
medications. The scenarios were pre-tested by 
experienced pharmacists for comprehension and 
readability, and were mailed to a convenience 
sample of 20 community pharmacists in Australia 
who had specialist asthma training from a previous 
study.9 None of the 20 pharmacists had seen the 
scenarios or the patients previously. 
Pharmacists were asked to record a prescribing 
intervention for each scenario, assuming 
unrestricted prescribing rights, or no intervention if 
appropriate. Prescribing was defined for the 
pharmacists as “adding or subtracting a medication, 
or altering a dose of medication”. Pharmacists could 
make more than one intervention for each scenario. 
Pharmacists were also asked to rate the usefulness 
of a prescribing function in his/her management of 
that scenario (scale: 1=not useful, 3=very useful) as 
well as his/her level of confidence in performing that 
intervention (scale: 1=not at all confident, 5=very 
confident). 
The Respiratory Therapeutic Guidelines34 were 
used to assess the appropriateness of pharmacists’ 
interventions by a panel of three expert researchers 
who independently scored the interventions 
(appropriate/inappropriate), and then met and 
discussed their interpretations in order to reach a 
consensus.  




Completed questionnaires were received from 
18/20 pharmacists. There was good agreement as 
to the appropriateness or inappropriateness of the 
interventions between researchers when assessed 
(ICC 0.705). In 7/9 scenarios the interventions 
made by the majority of the pharmacists were in line 
with guideline recommendations (Table 2). 
However, although the pharmacist interventions 
Table 1. Scenarios and expected prescribing interventions according to current guidelines 
Summarised scenario Expected prescribing intervention 
1: 74 y/o male with cough at night, overuse of salbutamol, FEV1 65% 
predicted 
Prescribe a single ingredient inhaled steroid 
2: 40 y/o female with poor asthma control, on regular fluticasone 250mcg 
twice daily 
Prescribe a long acting beta agonist (LABA) 
or combination inhaled steroid /LABA 
3: 74 y/o female with symptoms upon exertion, on regular budesonide 
200mcg/eformoterol 6mcg once daily, FEV1 75% predicted  
Increase dose of inhaled steroid 
4: 79 y/o female collecting salbutamol prescription, has had no symptoms in 
last 9 months  
No action 
5: 62 y/o female on fluticasone 500mcg/salmeterol 50mcg twice daily, and 
both salbutamol and ipratropium for relief 
Removal of second reliever 
6: 64 y/o female experiencing shortness of breath once a week whilst 
minding 2 y/o grandson. On fluticasone 250mcg/salmeterol 50mg twice 
daily, and both salbutamol and terbutaline nebules for relief 
Removal of nebulised medications 
7: 65 y/o male has a cold, with symptoms of “a lot of trouble breathing” and 
trouble sleeping. Usually on fluticasone 500mcg/salmeterol 50mcg twice 
daily and salbutamol for relief 
Prescribe a short course of an oral steroid 
8: 61 y/o female has had not had to use Ventolin for a very long time, feels 
well. On fluticasone 100mcg/salmeterol 50mcg twice daily 
Remove LABA 
9: 62 y/o male has not had any problems for two years. On fluticasone 
500mcg/salmeterol 50mcg twice daily and salbutamol for relief 
Reduce inhaled steroid dose 
Nine scenarios were modelled on information from real patients9 and the expected prescribing intervention was determined 
based on current Respiratory Therapeutic Guidelines (TG) for each scenario.34 
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were in-line (e.g., adding a long acting beta agonist) 
in the majority of scenarios, the pharmacists did not 
always execute their interventions relative to 
guideline recommendations (e.g., did not give 
complete directions or had alternative dosage). 
Therefore, due to the execution, many interventions 
were overall judged as inappropriate (86/162, 53%). 
The reasons they were considered inappropriate 
are as follows: 
1. Followed common practice (n=56/162) e.g. 
initiating steroid-naive patients on combination 
inhalers or medium/high doses of inhaled 
corticosteroids (ICS) (rather than low dose 
ICS);  
2. Clinically inappropriate (n=15/162) e.g. did not 
prescribe a short course of oral corticosteroids 
when appropriate, did not increase dose of 
ICS when required, prescribed antibiotics;  
3. No dose specified (n=8/162); and  
4. The pharmacist was hesitant (n=7/162) e.g. 
took no action or referred to the general 
practitioner (GP) when they could have made 
an intervention.  
So, although 53% of interventions were judged 
inappropriate, when consideration of common 
practice (i.e. what GPs do) was taken into account, 
81% of pharmacist’s decisions were in-line with 
common practice. 
A small number of interventions were considered 
clinically inappropriate (n= 23 [15+8]). This was 
usually about pharmacist inaction, e.g. they did not 
prescribe a short course of an oral corticosteroid or 
no dose was specified. 
Although pharmacists were asked to ensure that 
their interventions were of a prescribing nature only, 
a large proportion of pharmacists made 
interventions beyond the traditional prescribing 
function. Patient review and counselling were the 
most frequent additional interventions made by 
pharmacists. Spirometry was seen as an important 
tool to aid in the prescribing function and was often 
requested in the scenarios by pharmacists. 
Additionally, some pharmacists reported prescribing 
an action plan when treating patients in the 
scenarios. In a small number of scenarios, 
pharmacists felt the need to refer patients onto their 
GP rather than making any intervention themselves. 
When asked to rate the usefulness of a prescribing 
function in his/her management of each scenario, 
pharmacists rated this as ‘very useful’ (median 2.5; 
range of 2-3). When asked about their confidence in 
undertaking the stated prescribing interventions, 
pharmacists were ‘very confident’ (median 4). 
 
DISCUSSION 
This is the first Australian study exploring the utility 
of prescribing interventions by community 
pharmacists in the management of patients with 
asthma using a scenario based approach. There 
was a good understanding of appropriate 
therapeutic recommendations, however the 
execution of the pharmacists’ recommendations did 
not always agree with current guidelines. In 
overseas studies that have illustrated pharmacists’ 
abilities to identify appropriate drug therapy (in other 
diseases) and improve patient outcomes by 
prescribing roles35,36, pharmacists were offered 
specific training in, and frameworks for, prescribing. 
Similarly, Australian pharmacists would need 
specific training especially around the execution of 
prescribing interventions, which was not provided in 
this study. This would enable them to reach optimal, 
rather than acceptable, standards of practice in this 
extended role.  
Pharmacists demonstrated their holistic approach to 
asthma management by specifically suggesting that 
written Asthma Action Plans be provided. Although 
the deliverance of written Asthma Action Plans is 
recommended in asthma guidelines in Australia, 
ownership remains low at about 20%.1 The 
pharmacists added this as part of their prescribing 
interventions. 
Referral patterns identified the cautious nature of 
pharmacists in referring patients to a doctor 
whenever doubt existed and reflects the 
pharmacist’s ability to recognise the critical role of 
the physician, especially in diagnosis and review. 
This is contrary to common misconceptions of 
pharmacist prescribing as competition for 
doctors37,38, rather than an avenue for collaborative 
improvement of patient outcomes and a means of 
Table 2. Interventions recommended by pharmacists, using three scenarios as an example.  
Intervention Frequency (%) 
Scenario 2   
Combination steroid inhaler prescribed 59.1* 
No prescribing action taken 27.3 
Short acting beta agonist increased or SMART therapy 13.6 
Inhaled steroid dose increased 4.5 
Smoking cessation product prescribed 4.5 
Long acting beta agonist prescribed 4.5 
Scenario 8   
No prescribing action taken 68.4 
Inhaled steroid dose decreased 15.8 
Combination steroid inhaler changed 5.3 
Smoking cessation produce prescribed 5.3 
Long acting beta agonist removed 5.3* 
Scenario 9  
Inhaled steroid dose decreased 89.5* 
Smoking cessation product prescribed 5.3 
No prescribing action taken  5.3 
*Intervention that was in line with guideline recommendations for that scenario 
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reducing the physician’s burden. Appreciation of the 
expertise possessed by doctors, and its role in the 
prescribing process, is highlighted in other studies 
where pharmacists have specifically recognised 
that, even in a supplementary prescribing role, they 
would benefit from training in patient diagnosis, 
assessment and monitoring.24 This emphasis on the 
need for specific skills has been identified in other 
studies exploring pharmacist’s perspectives on 
postgraduate training opportunities to assist 
prescribing roles.27  
Although pharmacists were considered to make 
appropriate interventions based on guidelines, the 
execution of such interventions in the context of 
asthma management was deemed to be 
inappropriate in most scenarios. In the vast majority 
of these scenarios, pharmacists did not prescribe 
the recommended low starting doses of inhaled 
corticosteroids and often high doses of inhaled 
corticosteroids and combination therapy were 
prescribed.  
There are a number of possible reasons why these 
scenarios (n=86) were judged to be inappropriate 
when compared to guidelines. Firstly, although the 
pharmacists in this study received formal training on 
disease state management of asthma, the focus of 
such training was not on prescribing. This highlights 
the importance and need for further training and 
credentialing of Australian community pharmacists 
to ensure competent and appropriate prescribing is 
achieved.24-27,39-41 Secondly, pharmacists were not 
told in this study that their interventions would be 
assessed according to therapeutic guidelines, and 
interventions may therefore be reflective of common 
practice rather than evidence based practice. The 
non-adherence of physicians to prescribing 
guidelines is well described42,43, and our study 
illustrates that pharmacists may be influenced by 
their frequent exposure, through dispensing, to the 
‘common practice’ of physicians. Thirdly, in this 
study, mock scenarios were created depicting the 
clinical features of real life patients. Information 
about the core components of asthma control are 
considered necessary in making informed 
prescribing decisions for patients with asthma.44,45 
For practical purposes, the information provided to 
pharmacists about patients in the scenarios may 
have lacked the detail available in a real life 
prescribing setting. Thus pharmacist interventions 
may have differed with additional information 
accessible to them in a clinic setting. However, 
pharmacists are certainly capable of having in depth 
discussions with patients and gathering appropriate 
information from the patients to make fully informed 
prescribing decisions. If guideline appropriate and 
common clinical practice interventions are 
combined the proportion of appropriate prescribing 
was 81% across the nine scenarios. 
The pharmacists reported that having a prescribing 
role would be very useful in their management of 
these asthma patients. Even when making 
recommendations which were not consistent with 
the guidelines, most pharmacists expressed 
confidence in their prescribing interventions.  
Limitations 
The findings of the study might not be generalisable 
given the: selection of asthma specialist trained 
pharmacists who were untrained in prescribing or 
use of the guidelines; use of limited information in 
the scenarios; and small sample size. Pharmacist 
interventions may also have differed if they had 
been aware that they were being assessed 
according to therapeutic guidelines. None of the 
scenarios involved people under the age of 18. The 
pharmacists were selected because they had 
previously been involved in a trial focused on 
asthma care in the community.2,9 This trial focused 
on adults. Future studies should address people 
under 18 as well.  
 
CONCLUSIONS 
This study has provided encouraging results using 
scenarios to test the potential utility of prescribing 
by community pharmacists in primary care in 
Australia. These initial results should be used as a 
part of the basis for further research in determining 
the appropriateness of prescribing in actual practice 
and the training and skills required by pharmacists 
to successfully adopt an effective prescribing role. 
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EL USO DE ESCENARIOS PARA PROBAR LA 
ADECUACIÓN DE LA PRESCRIPCIÓN 
FARMACÉUTICA EN EL MANEJO DEL ASMA 
 
RESUMEN 
Objetivo: Explorar el potencial de prescripción de los 
farmacéuticos comunitarios en términos de utilidad, 
confianza de los farmacéuticos, y adecuación en el 
contexto del manejo del asma. 
Métodos: Se reclutó a 20 farmacéuticos comunitarios 
mediante un muestreo de conveniencia de entre un grupo 
de facultativos entrenados que ya habían proporcionado 
servicios en asma. Se pidió a estos farmacéuticos que 
completasen un cuestionario basado en escenarios (9 
escenarios) diseñados a partir de información de 
pacientes reales. Las intervenciones farmacéuticas fueron 
revisadas independientemente por 3 investigadores 
expertos y evaluada su adecuación de acuerdo con las 
Guías Terapéuticas Respiratorias (TG). 
Resultados: En 7 de los 9 escenarios (78%) la 
intervención prescriptora más frecuente de los 
farmacéuticos estaba de acuerdo con las 
recomendaciones de las TG. Aunque la intervención 
prescriptora era apropiada en la mayoría de los casos, la 
ejecución de esas intervenciones no estaba en línea con 
las guías (i.e. dosis o frecuencia) en la mayoría de los 
escenarios. Debido a esto, sólo el 47% (76/162) del total 
de las intervenciones fueron consideradas apropiadas. Sin 
embargo, se consideró que los farmacéuticos seguían con 
frecuencia la práctica clínica común de prescripción en 
asma. Por tanto, el 81% (136/162) de las intervenciones 
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prescriptivas fueron considerados consistente con la 
práctica clínica, que a menudo no está basada en las 
guías. Los farmacéuticos informaron que estaban 
confiados en la realización de intervenciones de 
prescripción y que esto sería muy útil en su manejo de los 
pacientes en los escenarios. 
Concusión: Los farmacéuticos comunitarios pueden ser 
capaces de prescribir medicación para el asma 
adecuadamente para ayudar a conseguir buenos 
resultados a sus pacientes. Sin embargo, se requiere más 
formación sobre las guías de prescripción, si los 
farmacéuticos desean apoyar el manejo del asma de esta 
manera. 
 
Palabras clave: Asma; Recetas; Servicios de Farmacia 
Comunitaria; Práctica Profesional; Papel Profesional; 
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